[go: up one dir, main page]

AU8866198A - Method for preparing vesicular nanocapsules - Google Patents

Method for preparing vesicular nanocapsules

Info

Publication number
AU8866198A
AU8866198A AU88661/98A AU8866198A AU8866198A AU 8866198 A AU8866198 A AU 8866198A AU 88661/98 A AU88661/98 A AU 88661/98A AU 8866198 A AU8866198 A AU 8866198A AU 8866198 A AU8866198 A AU 8866198A
Authority
AU
Australia
Prior art keywords
nanocapsules
vesicular nanocapsules
preparing
preparing vesicular
oily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU88661/98A
Inventor
Eric Allemann
Eric Doelker
Hatem Fessi
David Quintanar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Claude Bernard Lyon 1
Original Assignee
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Claude Bernard Lyon 1 filed Critical Universite Claude Bernard Lyon 1
Publication of AU8866198A publication Critical patent/AU8866198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer
    • Y10T428/2987—Addition polymer from unsaturated monomers only

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for the preparation of nanoparticles for the encapsulation of active constituents, the nanocapsules prepared being dispersible in aqueous phase in colloidal form, non-toxic, biocompatible, stable in colloidal suspension and economical. In the process, two non-oily solvents as used, together with a third, oily solvent.
AU88661/98A 1997-07-24 1998-07-21 Method for preparing vesicular nanocapsules Abandoned AU8866198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709672 1997-07-24
FR9709672A FR2766368B1 (en) 1997-07-24 1997-07-24 METHOD FOR PREPARING NANOCAPSULES OF THE VESICULAR TYPE, USABLE IN PARTICULAR AS COLLOIDAL VECTORS OF PHARMACEUTICAL OR OTHER ACTIVE PRINCIPLES
PCT/FR1998/001611 WO1999004766A1 (en) 1997-07-24 1998-07-21 Method for preparing vesicular nanocapsules

Publications (1)

Publication Number Publication Date
AU8866198A true AU8866198A (en) 1999-02-16

Family

ID=9509787

Family Applications (1)

Application Number Title Priority Date Filing Date
AU88661/98A Abandoned AU8866198A (en) 1997-07-24 1998-07-21 Method for preparing vesicular nanocapsules

Country Status (10)

Country Link
US (1) US6884438B1 (en)
EP (1) EP1003488B1 (en)
JP (1) JP2001510790A (en)
AT (1) ATE286388T1 (en)
AU (1) AU8866198A (en)
BR (1) BR9815562A (en)
CA (1) CA2297760A1 (en)
DE (1) DE69828513T2 (en)
FR (1) FR2766368B1 (en)
WO (1) WO1999004766A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US7838037B2 (en) 1999-11-17 2010-11-23 Tagra Biotechnologies Ltd. Method of microencapsulation
GB2356386A (en) 1999-11-17 2001-05-23 Tagra Biotechnologies Ltd Microencapsulation
FR2806005B1 (en) 2000-03-10 2002-06-14 Univ Claude Bernard Lyon PROCESS FOR THE PREPARATION OF COLLOIDAL PARTICLES IN THE FORM OF NANOCAPSULES
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
WO2003104307A1 (en) * 2002-06-10 2003-12-18 Rhodia Inc Phase-separated composition comprising two miscible solvents, and use thereof in a process for making capsules
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
WO2004111033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
FR2864900B1 (en) * 2004-01-09 2007-10-12 Oreal AQUEOUS DISPERSION OF NANOCAPSULES WITH OILY HEART
EP1909771A1 (en) * 2005-08-02 2008-04-16 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
WO2007062207A2 (en) * 2005-11-23 2007-05-31 Schering Corporation Methods for quantifying polymer attachment to a particle
DE102006011314A1 (en) 2006-03-11 2007-10-18 Peter Dr. Engels Cosmetic preparations containing an additive from the baobab plant
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
JP5571380B2 (en) 2006-07-24 2014-08-13 ルミナス バイオサイエンシズ，インコーポレイテッド Solid nanoparticle formulations of water-insoluble pharmaceutical substances with reduced Ostwald ripening
FR2918888B1 (en) * 2007-07-18 2009-10-23 Centre Nat Rech Scient CONTROLLED DELIVERY SYSTEM OF ACTIVE INGREDIENT AND PREPARATION METHOD
FR2930176B1 (en) * 2008-04-18 2011-03-18 Univ Claude Bernard Lyon NOVEL PROCESS FOR THE PRODUCTION OF NANOCAPSULES, IN THE ABSENCE OF ORGANIC SOLVENT, AND NANOCAPSULES SO OBTAINED
FR3061033A1 (en) * 2016-12-22 2018-06-29 Centre National De La Recherche Scientifique PROCESS FOR THE PREPARATION OF SOLUTE NANOCAPSULES AND USE THEREOF

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2010115A1 (en) * 1970-03-04 1971-09-16 Farbenfabriken Bayer Ag, 5090 Leverkusen Process for the production of micro-granules
EP0007895B1 (en) * 1978-07-19 1983-06-22 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
AU610594B2 (en) * 1987-04-16 1991-05-23 Christian Bindschaedler Process for preparing a powder of water-insoluble polymer which can be redispersed in a liquid phase, the resulting powder and utilization thereof
FR2660193B1 (en) * 1990-04-03 1994-11-04 Philippe Maincent OPTHALMIC PRODUCT COMPRISING NANOCAPSULES, PROCESS FOR THE PREPARATION AND USE OF NANOCAPSULES.
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
TW493991B (en) * 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
DE19545257A1 (en) * 1995-11-24 1997-06-19 Schering Ag Process for the production of morphologically uniform microcapsules and microcapsules produced by this process

Also Published As

Publication number Publication date
FR2766368B1 (en) 2000-03-31
ATE286388T1 (en) 2005-01-15
BR9815562A (en) 2001-01-16
DE69828513D1 (en) 2005-02-10
CA2297760A1 (en) 1999-02-04
US6884438B1 (en) 2005-04-26
FR2766368A1 (en) 1999-01-29
WO1999004766A1 (en) 1999-02-04
EP1003488A1 (en) 2000-05-31
DE69828513T2 (en) 2006-01-05
EP1003488B1 (en) 2005-01-05
JP2001510790A (en) 2001-08-07

Similar Documents

Publication Publication Date Title
AU8866198A (en) Method for preparing vesicular nanocapsules
EP1020460A3 (en) The sodium salt of the (-)-enantiomer of omeprazole
AU4494499A (en) Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AUPN969796A0 (en) Taste masked liquid suspensions
AU2001240753A1 (en) Lipid nanocapsules, preparation method and use as medicine
AU3702895A (en) Process for preparing solid pharmaceutical dosage forms
EP1136068A3 (en) Powder containing physiologically active peptide
CA2113243A1 (en) Pharmaceutical compositions containing nanocapsules
AU2890795A (en) Novel quaternary ammonium derivatives, preparation method therefor and use thereof as surfactants
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
HUP9601884A2 (en) 6-(dimethylamino-methyl)-1-phenyl-cyclohexane compounds, their use as pharmaceutically active analgetic matarials and process for their preparation
EP1642571A3 (en) Method for preparing submicron particle suspensions
CA2199679A1 (en) Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients
CA2222811A1 (en) Stabilized solid dispersions of misoprostol
AU2731999A (en) Stable homogeneous emulsifier-free suspension, preparation method and uses in food compositions
AU3028897A (en) New guanidine derivatives, methods of preparing them, and their use as drugs
AU2001262011A1 (en) A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component
CA2259520A1 (en) Preparation for injection containing a lipid a analog and process for preparing the same
EP1302207A3 (en) Method for preparing an antihypertensive agent containing a dipeptide as active ingredient
AU1470195A (en) Nanoparticles containing an active substance and a ketalizedpolytartramidic acid, process for their preparation, and use thereof
CA2320878A1 (en) Morphine sulphate microgranules, method for making same and pharmaceutical preparations
CA2326840A1 (en) Carvedilol-galenics
CA2173642A1 (en) Process for Derivatizing Polyglucosamines
AU692030B2 (en) Hydantoin derivatives, process for producing the same and herbicides comprising the same as active ingredients
AU3290200A (en) Treatment agents for textiles, method of producing same and their use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase